Received Mar 10, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | — |
pain and redness at the injection site; pain and redness at the injection site; This non-serious case was reported by a consumer via patient support programs and described the occurrence of injection site pain in a 55-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. In SEP-2024, the patient received the 1st dose of Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site pain (Verbatim: pain and redness at the injection site) and injection site erythema (Verbatim: pain and redness at the injection site). The outcome of the injection site pain and injection site erythema were not reported. It was unknown if the reporter considered the injection site pain and injection site erythema to be related to Shingrix. It was unknown if the company considered the injection site pain and injection site erythema to be related to Shingrix. Additional Information: GSK Receipt Date: 24-FEB-2025 The patient was the reporter. The patient was a 55-year-old female that received her first Shingrix vaccine in September 2024 (unsure of exact date). The reporter stated that after the first vaccination she had mild common symptoms as far as pain and redness at the injection site.